VivoSeq
Other

Polyp

1

Pipeline Programs

2

Active Trials

1

Companies Involved

Polyp is an early-stage landscape with 1 program across 1 company. The most active players are Fresenius Kabi Oncology Ltd.. 1 therapy is approved.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

85/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs

Trial Status

18

clinical trials

Completed11 · 61%
Unknown status3 · 17%
Recruiting2 · 11%
Terminated1 · 6%
Withdrawn1 · 6%

Trial Activity

18 trials

Cross-over Study of Coronary Risk Factors With a Polypill
Recruiting·FFundación EPIC·Phase 4·NCT05030818·88 enrolled
Medical Polypectomy and Predictors of Response
Completed·UUniversity of Dundee·Phase 4·NCT00788749·60 enrolled
The Evening Versus Morning Polypill Utilization Study
Completed·UUMC Utrecht·N/A·NCT01506505·78 enrolled
The SCCS Polypill Pilot Trial
Completed·VVanderbilt University·Phase 2·NCT02278471·303 enrolled
Effect of Epinephrine on Post-polypectomy Pain
Completed·IIndiana University·Phase 4·NCT04065451·22 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)